Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement

Abstract The study evaluated the efficacy of ID-JPL934, a probiotic preparation containing Lactobacillus johnsonii IDCC 9203, Lactobacillus plantarum IDCC 3501 and Bifidobacterium lactis IDCC 4301, in relieving lower gastrointestinal symptoms. A total of 112 subjects with lower gastrointestinal symp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cheol Min Shin, Yoon Jin Choi, Dong Ho Lee, Jin Seok Moon, Tae-Yoon Kim, Yoon-Keun Kim, Won-Hee Lee, Hyuk Yoon, Young Soo Park, Nayoung Kim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a60bc0717083457d810206a5bd4207e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a60bc0717083457d810206a5bd4207e2
record_format	dspace
spelling	oai:doaj.org-article:a60bc0717083457d810206a5bd4207e22021-12-02T17:45:17ZValidity and safety of ID-JPL934 in lower gastrointestinal symptom improvement10.1038/s41598-021-92007-32045-2322https://doaj.org/article/a60bc0717083457d810206a5bd4207e22021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92007-3https://doaj.org/toc/2045-2322Abstract The study evaluated the efficacy of ID-JPL934, a probiotic preparation containing Lactobacillus johnsonii IDCC 9203, Lactobacillus plantarum IDCC 3501 and Bifidobacterium lactis IDCC 4301, in relieving lower gastrointestinal symptoms. A total of 112 subjects with lower gastrointestinal symptoms were consecutively enrolled. They were randomized into either ID-JPL934 administration group or placebo group. Bristol stool form, stool frequency, and abnormal bowel movement symptoms were recorded at baseline and week 2, 6, and 8. Primary endpoint was improvement in overall symptoms at week 8. Fecal samples were collected to measure the probiotic levels in feces using quantitative polymerase chain reaction (qPCR), and to perform metagenomic analysis of microbiome originating from bacteria-derived extracellular vesicles and bacterial cells via 16S rDNA sequencing. Of the 112 subjects, 104 (54 in ID-JPL934 group and 50 in placebo group) completed the entire study protocol. A higher relief of overall symptoms was found in ID-JPL934 group than in placebo group (p = 0.016). Among lower gastrointestinal symptoms, abdominal pain and bloating scores were more decreased in ID-JPL934 group than in placebo group (p < 0.05). The fecal microbiome profiles of the two groups did not differ. However, the qPCR analysis showed significant increase in the levels of Lactobacillus johnsonii and Bifidobacterium lactis in feces post-treatment in ID-JPL934 group than in placebo group (p < 0.05 by repeated measure ANOVA). In conclusion, ID-JPL934 is effective in relieving lower gastrointestinal symptoms. Exposure to ID-JPL934 may increase the abundance of Lactobacillus johnsonii and Bifidobacterium lactis in the gut. Trial registration: ClinicalTrials.gov number, NCT03395626.Cheol Min ShinYoon Jin ChoiDong Ho LeeJin Seok MoonTae-Yoon KimYoon-Keun KimWon-Hee LeeHyuk YoonYoung Soo ParkNayoung KimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Cheol Min Shin Yoon Jin Choi Dong Ho Lee Jin Seok Moon Tae-Yoon Kim Yoon-Keun Kim Won-Hee Lee Hyuk Yoon Young Soo Park Nayoung Kim Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement
description	Abstract The study evaluated the efficacy of ID-JPL934, a probiotic preparation containing Lactobacillus johnsonii IDCC 9203, Lactobacillus plantarum IDCC 3501 and Bifidobacterium lactis IDCC 4301, in relieving lower gastrointestinal symptoms. A total of 112 subjects with lower gastrointestinal symptoms were consecutively enrolled. They were randomized into either ID-JPL934 administration group or placebo group. Bristol stool form, stool frequency, and abnormal bowel movement symptoms were recorded at baseline and week 2, 6, and 8. Primary endpoint was improvement in overall symptoms at week 8. Fecal samples were collected to measure the probiotic levels in feces using quantitative polymerase chain reaction (qPCR), and to perform metagenomic analysis of microbiome originating from bacteria-derived extracellular vesicles and bacterial cells via 16S rDNA sequencing. Of the 112 subjects, 104 (54 in ID-JPL934 group and 50 in placebo group) completed the entire study protocol. A higher relief of overall symptoms was found in ID-JPL934 group than in placebo group (p = 0.016). Among lower gastrointestinal symptoms, abdominal pain and bloating scores were more decreased in ID-JPL934 group than in placebo group (p < 0.05). The fecal microbiome profiles of the two groups did not differ. However, the qPCR analysis showed significant increase in the levels of Lactobacillus johnsonii and Bifidobacterium lactis in feces post-treatment in ID-JPL934 group than in placebo group (p < 0.05 by repeated measure ANOVA). In conclusion, ID-JPL934 is effective in relieving lower gastrointestinal symptoms. Exposure to ID-JPL934 may increase the abundance of Lactobacillus johnsonii and Bifidobacterium lactis in the gut. Trial registration: ClinicalTrials.gov number, NCT03395626.
format	article
author	Cheol Min Shin Yoon Jin Choi Dong Ho Lee Jin Seok Moon Tae-Yoon Kim Yoon-Keun Kim Won-Hee Lee Hyuk Yoon Young Soo Park Nayoung Kim
author_facet	Cheol Min Shin Yoon Jin Choi Dong Ho Lee Jin Seok Moon Tae-Yoon Kim Yoon-Keun Kim Won-Hee Lee Hyuk Yoon Young Soo Park Nayoung Kim
author_sort	Cheol Min Shin
title	Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement
title_short	Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement
title_full	Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement
title_fullStr	Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement
title_full_unstemmed	Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement
title_sort	validity and safety of id-jpl934 in lower gastrointestinal symptom improvement
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a60bc0717083457d810206a5bd4207e2
work_keys_str_mv	AT cheolminshin validityandsafetyofidjpl934inlowergastrointestinalsymptomimprovement AT yoonjinchoi validityandsafetyofidjpl934inlowergastrointestinalsymptomimprovement AT dongholee validityandsafetyofidjpl934inlowergastrointestinalsymptomimprovement AT jinseokmoon validityandsafetyofidjpl934inlowergastrointestinalsymptomimprovement AT taeyoonkim validityandsafetyofidjpl934inlowergastrointestinalsymptomimprovement AT yoonkeunkim validityandsafetyofidjpl934inlowergastrointestinalsymptomimprovement AT wonheelee validityandsafetyofidjpl934inlowergastrointestinalsymptomimprovement AT hyukyoon validityandsafetyofidjpl934inlowergastrointestinalsymptomimprovement AT youngsoopark validityandsafetyofidjpl934inlowergastrointestinalsymptomimprovement AT nayoungkim validityandsafetyofidjpl934inlowergastrointestinalsymptomimprovement
_version_	1718379605357756416

Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement

Ejemplares similares